Seattle Genetics Inc. (SGEN) is priced at $158.34 after the most recent trading session. At the very opening of the session, the stock price was $152.49 and reached a high price of $159.035, prior to closing the session it reached the value of $153.66. The stock touched a low price of $152.48.
Recently in News on August 27, 2020, Seattle Genetics to Receive Milestone Payment Under ADC Collaboration with GlaxoSmithKline Following European Commission Approval of BLENREP (belantamab mafodotin). Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that it will receive a milestone payment from GlaxoSmithKline (GSK) triggered by European Commission conditional marketing authorisation for GSK’s BLENREP™ (belantamab mafodotin), an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA) that utilizes Seattle Genetics’ proprietary technology. BLENREP was developed and will be commercialized by GSK. In addition to the milestone payment, Seattle Genetics is entitled to royalties on BLENREP product sales. BLENREP was approved as monotherapy for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy. You can read further details here
Seattle Genetics Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $187.99 on 07/20/20, with the lowest value was $90.57 for the same time period, recorded on 03/16/20.
Seattle Genetics Inc. (SGEN) full year performance was 117.98%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Seattle Genetics Inc. shares are logging -15.77% during the 52-week period from high price, and 141.96% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $65.44 and $187.99.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1224542 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Seattle Genetics Inc. (SGEN) recorded performance in the market was 38.58%, having the revenues showcasing -1.54% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 27.63B, as it employees total of 1605 workers.
Specialists analysis on Seattle Genetics Inc. (SGEN)
During the last month, 11 analysts gave the Seattle Genetics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 7 analysts were recommending to HOLD this stock, 1 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 158.39, with a change in the price was noted +38.66. In a similar fashion, Seattle Genetics Inc. posted a movement of +32.30% for the period of last 100 days, recording 1,149,518 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for SGEN is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Trends and Technical analysis: Seattle Genetics Inc. (SGEN)
Raw Stochastic average of Seattle Genetics Inc. in the period of last 50 days is set at 18.64%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 39.52%. In the last 20 days, the company’s Stochastic %K was 20.13% and its Stochastic %D was recorded 13.10%.
Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 38.58%. Additionally, trading for the stock in the period of the last six months notably improved by 47.43%, alongside a boost of 117.98% for the period of the last 12 months. The shares increased approximately by 2.25% in the 7-day charts and went up by -4.77% in the period of the last 30 days. Common stock shares were lifted by -1.54% during last recorded quarter.